Analysts expect Flexion Therapeutics, Inc. (NASDAQ:FLXN) to report $-1.09 EPS on March, 8.They anticipate $0.31 EPS change or 39.74% from last quarter’s $-0.78 EPS. After having $-1.07 EPS previously, Flexion Therapeutics, Inc.’s analysts see 1.87% EPS growth. The stock decreased 1.97% or $0.51 during the last trading session, reaching $25.36. About 749,750 shares traded. Flexion Therapeutics, Inc. (NASDAQ:FLXN) has risen 82.02% since March 1, 2017 and is uptrending. It has outperformed by 65.32% the S&P500.
Among 4 analysts covering Concordia Healthcare Corp (TSE:CXR), 0 have Buy rating, 3 Sell and 1 Hold. Therefore 0 are positive. Concordia Healthcare Corp had 34 analyst reports since August 11, 2015 according to SRatingsIntel. Goldman Sachs maintained the shares of CXR in report on Friday, July 22 with “” rating. On Friday, January 8 the stock rating was maintained by RBC Capital Markets with “Outperform”. The rating was maintained by Scotia Capital on Wednesday, January 4 with “Underperform”. The rating was maintained by RBC Capital Markets with “Outperform” on Monday, June 20. RBC Capital Markets maintained the stock with “Outperform” rating in Tuesday, August 11 report. The rating was maintained by Scotia Capital on Thursday, March 16 with “Underperform”. The stock of Concordia International Corp. (TSE:CXR) earned “Outperform” rating by RBC Capital Markets on Monday, October 31. The firm has “Outperform” rating by RBC Capital Markets given on Monday, October 24. As per Wednesday, September 9, the company rating was maintained by Scotia Capital. The rating was downgraded by Mackie to “Hold” on Thursday, December 3. See Concordia International Corp. (TSE:CXR) latest ratings:
Among 10 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Flexion Therapeutics had 22 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Flexion Therapeutics, Inc. (NASDAQ:FLXN) has “Buy” rating given on Thursday, July 21 by Lake Street. The firm has “Buy” rating given on Tuesday, October 24 by RBC Capital Markets. RBC Capital Markets maintained the stock with “Buy” rating in Monday, September 11 report. RBC Capital Markets maintained the shares of FLXN in report on Friday, July 7 with “Buy” rating. On Tuesday, May 3 the stock rating was reinitiated by Wells Fargo with “Outperform”. As per Monday, October 30, the company rating was maintained by Wells Fargo. The stock of Flexion Therapeutics, Inc. (NASDAQ:FLXN) has “Buy” rating given on Monday, June 26 by BMO Capital Markets. As per Monday, June 12, the company rating was maintained by Cantor Fitzgerald. The company was initiated on Wednesday, June 29 by BMO Capital Markets. The stock of Flexion Therapeutics, Inc. (NASDAQ:FLXN) has “Outperform” rating given on Monday, October 9 by BMO Capital Markets.
Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company has market cap of $952.04 million. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. It currently has negative earnings.
Investors sentiment decreased to 1.22 in 2017 Q3. Its down 0.52, from 1.74 in 2017Q2. It turned negative, as 13 investors sold Flexion Therapeutics, Inc. shares while 28 reduced holdings. 22 funds opened positions while 28 raised stakes. 26.01 million shares or 2.53% more from 25.36 million shares in 2017Q2 were reported. Geode Cap Management Lc reported 224,843 shares. Eaton Vance has invested 0% in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Moreover, Scholtz & Com has 1.05% invested in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Raymond James Services Advsrs reported 71,320 shares. Moreover, Legal General Grp Plc has 0% invested in Flexion Therapeutics, Inc. (NASDAQ:FLXN). 800 were accumulated by Northwestern Mutual Wealth Management. Mark Sheptoff Financial Planning Ltd Liability Corporation invested in 1,100 shares. Tpg Grp (Sbs), a Texas-based fund reported 936,507 shares. Virginia Retirement Et Al invested in 20,500 shares. Highbridge Cap holds 0.02% or 50,823 shares in its portfolio. Mirae Asset Glob Invests Limited, a Korea-based fund reported 171,338 shares. Wells Fargo & Communications Mn owns 151,849 shares. Pub Employees Retirement Of Ohio has 41,644 shares. 2.54M are owned by Capital Ww. Zurcher Kantonalbank (Zurich Cantonalbank) reported 3,149 shares or 0% of all its holdings.
Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company has market cap of $41.54 million. It operates through three divisions: Concordia International, Concordia North America, and Orphan Drugs. It currently has negative earnings. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.
The post Flexion Therapeutics, Inc. (FLXN) Analysts See $-1.09 EPS; 0 Analysts Are Bullish Concordia International Corp. (TSE:CXR) Last Week appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2018/03/01/flexion-therapeutics-inc-flxn-analysts-see-1-09-eps-0-analysts-are-bullish-concordia-international-corp-tsecxr-last-week/
No comments:
Post a Comment